Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin
Rattachement africain : it, us, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To evaluate the impact of age on oncological outcomes in a large contemporary cohort of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adequate Bacillus Calmette-Guérin (BCG). PATIENTS AND METHODS: We performed an Institutional Review Board-approved retrospective study analysing patients with NMIBC treated with adequate BCG at our institution from 2000 to 2020. Adequate BCG was defined as per United States Food and Drug Administration (FDA) guidelines as being receipt of at least five of six induction BCG instillations with a minimum of two additional doses (of planned maintenance or of re-induction) of BCG instillations within a span of 6 months. The study's primary outcome was to determine if age >70 years was associated with progression to MIBC cancer or distant metastasis. The cumulative incidence method and the competing-risk regression analyses were used to investigate the association of advanced age (>70 years) with progression, high-grade (HG) recurrence and cancer-specific mortality (CSM). RESULTS: Overall, data from 632 patients were analysed: 355 patients (56.2%) were aged ≤70 years and 277 (43.8%) were >70 years. Age >70 years did not adversely affect either cumulative incidence of progression or HG recurrence (P = 0.067 and P = 0.644, respectively). On competing-risk regression analyses, age >70 years did not emerge as an independent predictor of progression or HG recurrence (sub-standardised hazard ratio [SHR] 1.57, 95% confidence interval [CI] 0.87-2.81, P = 0.134; and SHR 1.05, 95% CI 0.77-1.44, P = 0.749). Not unexpectedly, patients in the older group did have higher overall mortality (P < 0.001) but not CSM (P = 0.057). CONCLUSION: Age >70 years was not associated with adverse oncological outcomes in a large contemporary cohort of patients receiving adequate intravesical BCG for NMIBC. BCG should not be withheld from older patients seeking for bladder sparing options.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin
- Date Crossref
- 02/08/2023
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Humanitas University pays non établi dans la noticeUniversité ou école supérieure
-
The University of Texas MD Anderson Cancer Center Department of Urology pays non établi dans la noticeÉtablissement de santé
-
University of Kentucky Department of Urology pays non établi dans la noticeUniversité ou école supérieure
-
Guy's and St Thomas' NHS Foundation Trust Department of Urology pays non établi dans la noticeÉtablissement de santé
-
Department of Urology University of Texas MD Anderson Cancer Center Houston TX USA pays non établi dans la noticeUniversité ou école supérieure
-
Department of Biostatistics University of Texas MD Anderson Cancer Center Houston TX USA pays non établi dans la noticeUniversité ou école supérieure
-
Department of Pathology University of Texas MD Anderson Cancer Center Houston TX USA pays non établi dans la noticeUniversité ou école supérieure
Humanitas University, Department of Urology — The University of Texas MD Anderson Cancer Center et Department of Urology — University of Kentucky, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.